文献速递血液净化与透析

血液透析滤过与血液透析患者的死亡风险:DOPPS真实世界比较

Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

基于DOPPS第4-5期(2009-15)7个欧洲国家8567例透析>90天患者,2012例(23%)使用HDF。校正后HDF vs HD全因死亡HR为1.14(95%CI 1.00-1.29),HDF>20L置换液量vs HD为1.08(0.92-1.28)。结果不支持HDF提供更优生存。

要点

  • 真实世界DOPPS数据显示HDF与HD全因死亡风险无显著改善。
  • 高置换液量HDF(>20L)较HD的死亡HR为1.08(0.92-1.28)。
  • 需进一步RCT比较不同置换液量HDF与HD的临床结局。

核心结论

  • HDF与HD相比未显示更优的患者生存,全因死亡HR为1.14(95%CI 1.00-1.29)。

研究设计与样本

  • DOPPS第4-5期(2009-15)真实世界分析,纳入7个欧洲国家透析>90天患者8567例,其中2012例(23%)使用HDF。

主要发现

  • 中位随访1.5年,1988例死亡;校正后HDF vs HD全因死亡HR 1.14(95%CI 1.00-1.29)。
  • HDF>20L置换液量 vs HD全因死亡HR 1.08(95%CI 0.92-1.28)。
  • 心血管死亡和感染相关死亡结果与全因死亡相似。
  • 在避免治疗指征偏倚的附加分析中,使用更多HDF的机构未观察到更低死亡率。

临床怎么用

  • 当前证据不支持将HDF作为改善生存的常规优选方案,临床决策需个体化。

局限性

  • 观察性设计,可能存在残余混杂和治疗指征偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With its convective component, hemodiafiltration (HDF) provides better middle molecule clearance compared with hemodialysis (HD) and is postulated to improve survival. A previous analysis of Dialysis Outcomes and Practice Patterns Study (DOPPS) data in 1998-2001 found lower mortality rates for high replacement fluid volume HDF versus HD. Randomized controlled trials have not shown uniform survival advantage for HDF; in secondary (non-randomized) analyses, better outcomes were observed in patients receiving the highest convection volumes. METHODS: In a 'real-world' setting, we analyzed patients on dialysis >90 days from seven European countries in DOPPS Phases 4 and 5 (2009-15). Adjusted Cox regression was used to study HDF (versus HD) and mortality, overall and by replacement fluid volume. RESULTS: Among 8567 eligible patients, 2012 (23%) were on HDF, ranging from 42% in Sweden to 12% in Germany. Median follow-up was 1.5 years during which 1988 patients died. The adjusted mortality hazard ratio (95% confidence interval) was 1.14 (1.00-1.29) for any HDF versus HD and 1.08 (0.92-1.28) for HDF >20 L replacement fluid volume versus HD. Similar results were found for cardiovascular and infection-related mortality. In an additional analysis aiming to avoid treatment-by-indication bias, we did not observe lower mortality rates in facilities using more HDF (versus HD). CONCLUSIONS: Our results do not support the notion that HDF provides superior patient survival. Further trials designed to test the effect of high-volume HDF (versus lower volume HDF versus HD) on clinical outcomes are needed to adequately inform clinical practices.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Karaboyas A, Pisoni RL, et al. Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS. Nephrol Dial Transplant. 2018. PMID: 29040687. doi:10.1093/ndt/gfx277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。